Humoral and T-cell responses to a third dose of BNT162b2 and mRNA-1273 COVID-19 Vaccine in Patients with hematological diseases treated with rituximab or obinutuzumab: An observational study. - Rituximab or obinutuzumab a third dose study

Kobe City Medical Center General Hospital, Department of Hematology0 个研究点目标入组 68 人开始时间: 2022年1月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who are judged inappropriate for participation in the study by the investigators 2) Patients who have previously received rituximab for non-hematological diseases (polyangiitis granulomatosa, microscopic polyangiitis, refractory nephrotic syndrome) 3) Patients with a history of COVID-19 4) Patients with autoimmune diseases other than chronic idiopathic thrombocytopenic purpura (systemic lupus erythematosus, Sjogren's syndrome, dermatomyositis/polymyositis, mixed connective tissue disease, systemic scleroderma, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, spondyloarthritis and related diseases, vasculitis syndromes, inflammatory bowel disease, Guillain-Barre syndrome, and inflammatory bowel disease) Guillain-Barre syndrome, multiple sclerosis, neuromyelitis optica). 5) Patients who are unable to communicate with others

发起方

Kobe City Medical Center General Hospital, Department of Hematology